Clinical Study

A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study Of Risankizumab Compared To Ustekinumab For The Treatment Of Adult Subjects With Moderate To Severe Crohn's Disease Who Have Failed Anti-Tnf Therapy

Posted Date: Sep 21, 2021

  • Investigator: Loren Brook
  • Specialties:
  • Type of Study: Drug

This study will compare the efficacy and safety of risankizumab versus ustekinumab for the treatment of adult subjects with moderate to severe Crohn's disease (CD) who have failed anti-TNF therapy.


Age 18-80. Diagnosis Of Crohn's Disease For At Least 3 Months Prior To Screening. Willing And Able To Comply With Procedures Required In The Protocol.


Crohn's Disease, Crohn's

For More Information:

Missy Randolph

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.